In this issue of the journal, Ogdie and colleagues 1 report some variability in increased risk of venous thromboembolism (VTE) among individuals with three chronic inflammatory diseases (psoriatic arthritis, psoriasis, and rheumatoid arthritis) relative to unaffected control subjects, as well as some differences in attained statistical significance according to severity and treatments used for these conditions. Findings of associations of inflammatory diseases with risk of VTE are not new, but consideration of differences in these associations offers the hope of shedding light on the several unclear aspects of the role of inflammation in the development of VTE. The study of Ogdie and colleagues has some clear strengths, including its population-based study design, large study size, longterm follow-up leading to identification of substantial numbers of VTE events, and consideration of multiple confounding variables. Limitations include lack of control of duration of inflammatory disease through focus on prevalent cases, use of a disease-free referent group, with likely differential surveillance relative to the affected subjects, and reliance on regression model techniques to control for some substantial differences in confounder distributions across groups. Comparisons of treated individuals with prevalent conditions with untreated controls can introduce substantial biases that cannot be alleviated with regression model techniques. 2 Focus on newly diagnosed individuals compared with controls with other new-onset conditions associated with comparable surveillance can substantially reduce these biases. 3 Individuals in the tails of the propensity to receive treatments such as disease-modifying anti-rheumatic drugs (DMARDs) can be quite different from non-user controls, and their inclusion in analyses can lead to biases. 4 The authors address some of these concerns through sensitivity analyses. Overall, the study produces evidence of some increase in risk of VTE associated with these inflammatory diseases, but confidence intervals for estimated associations are generally overlapping, for either the main or key sensitivity analyses, leaving uncertainties about the implications of possible heterogeneity across these diseases.
In light of the additional evidence for a role for inflammation in the development of VTE, one may wonder whether efforts to lower inflammation can impact risk of VTE. From a public health perspective, it might be most effective for such efforts to target simultaneously other diseases with inflammatory aetiologies. 5 For example, it is natural to hypothesize that anti-inflammatory therapies might influence risks of both arterial and venous thrombosis. While these conditions have some clear distinctions in their risk factors (Figure 1 ), evidence that chronic inflammation plays a key role in the pathophysiology of both is mounting. Here we summarize some of the lifestyle, over-the-counter, and prescription treatments that might be effective for this purpose.
Lifestyle strategies
Elevated body mass index is a powerful risk factor for VTE, with evidence that its impact on relative risk of VTE is substantially greater than for coronary heart disease or stroke. 6, 7 It is natural to hypothesize that strategies to reduce weight, or to limit the common weight gain that occurs through mid life in developed countries, could reduce VTE risk. Beyond weight loss, diet can theoretically influence risk of VTE, particularly insofar as alternative diets can reduce measures of inflammation. However, evidence to date from epidemiological studies has found limited associations between adherence to heart healthy diets and risk of VTE. 8 It remains to be seen in a randomized trial whether dietary interventions to reduce measures of inflammation, either alone or together with weight loss, can also reduce risk of VTE. Nutritional supplements, especially anti-oxidant vitamins, have also been extensively studied for their possible impact on cardiovascular It is possible that the anticoagulant effect of vitamin E leads to some reduction in risk of VTE. However, in light of absence of benefit on the specified primary endpoints, and possible hazards on haemorrhagic stroke, such supplementation may have limited value. Exercise is another potential lifestyle strategy to influence risk of VTE. However, exercise regimens including vigorous approaches have uncertain associations with VTE risk, 6, 7 in contrast to demonstrated protective associations with cardiovascular risk. In fact, vigorous exercise among participants in the Physicians' Health Study was associated with a decrease in risk of coronary heart disease, but a small but significant increase in the risk of incident VTE. 7 Nonetheless, strategies to improve flexibility and possibly also reduce inflammation with little risk of injury, such as tai chi, could have benefits in the reduction of risk of VTE.
Aspirin and NSAIDs
No anti-inflammatory agent has been studied more carefully for its impact on VTE than aspirin. Older randomized trials showed reductions in risk of VTE associated with short-term aspirin therapy in orthopaedic surgical, general surgical, and high-risk medical patients. 10 More recent randomized trials of aspirin therapy in patients with a first unprovoked VTE who had completed anticoagulant treatment found a significant reduction in risk of recurrent VTE (hazard ratio 0.68; 95% CI 0.51-0.90) associated with 100 mg of aspirin daily. 11 However, benefits of long-term aspirin use for primary prevention of VTE are unclear. Among 39 876 women randomized in the Women's Health Study to 100 mg of aspirin on alternate days or placebo and followed for 10 years, 10 little benefit of aspirin therapy was found (relative hazard associated with aspirin treatment 0.95; 95% CI 0.79-1.13). Further, no significant benefits were noted in higher risk subgroups of women who reported a history of prior VTE at baseline, or in those with either the factor V Leiden or the prothrombin mutation. Further, women randomized to active aspirin had significant elevations in rates of each of gastrointestinal bleeding requiring transfusion, peptic ulcer, haematuria, easy bruising, and epistaxis. Randomized trials that evaluated non-steroidal anti-inflammatory drugs (NSAIDs) have not been large enough and of long enough duration to obtain reliable evidence on risks of VTE. A meta-analysis of six large observational studies 12 found a significant increased risk of VTE associated with NSAID use (relative risk 1.80; 95% CI 1.3-2.5). However, this meta-analysis noted considerable heterogeneity across studies, and comparisons of NSAID users with non-user referent subjects are particularly prone to confounding bias. Several characteristics associated with NSAID initiation, including obesity, immobility, injury, and pain are typically not measured well in observational studies.
Statins
In addition to their impact on lipid levels, statins exhibit pleiotropic effects, including beneficial effects on thrombosis and inflammation. 13 Indeed, any benefit of statins on risk of VTE is unlikely to be mediated by lipid changes, as dyslipidaemia has no apparent association with VTE risk. 6, 7 Now two randomized trials, both testing rosuvastatin vs.
placebo in the primary prevention of cardiovascular disease, have found substantial reductions in risk of VTE associated with active treatment. In the JUPITER trial, 13 individuals randomized to 20 mg daily of rosuvastatin had a 43% reduction in the hazard of VTE (hazard ratio 0.57; 95% CI 37-0.86), whereas in the HOPE-3 trial, 14 individuals randomized to 10 mg daily of rosuvastatin had a 55% reduction in the hazard of VTE (hazard ratio 0.45; 95% CI 0.24-0.84).
Although the mechanism of action remains to be specified, and the total number of VTE events in the two trials is <200, these consistent findings suggest a potentially important additional benefit of statin therapy, with a likely anti-inflammatory pathway.
Targeted anti-inflammatory therapy
Studies such as that of Ogdie et al. support the hypothesis that specific targeting of inflammation may reduce risk of VTE. Previous observational studies have suggested a benefit of DMARDs on risk of arterial thrombosis. Ability to draw a causal inference regarding the effects of these drugs on risk of either venous or arterial thrombosis based on observational data is greatly challenged by confounding by indication, typically limited assessment of disease severity in most observational studies, and absence of a comparison group of subjects in treatment equipoise. Randomized trials of anti-inflammatory therapies, primarily focused on their impact on risk of cardiovascular events, have also pre-specified incident VTE as a secondary outcome. 15 Specifically, the CANTOS trial has randomized >10 000 subjects with a previous myocardial infarction and elevated C-reactive protein to placebo or one of three doses of canakinumab, a human monoclonal antibody that specifically inhibits interleukin-1b and is known to lower downstream biomarkers such as C-reactive protein. After a median follow-up over 3.5 years, the trial has accrued its targeted number of primary endpoints, and is expected to report results later in 2017. In parallel, the CIRT trial has now randomized >4000 subjects with previous myocardial infarction or multivessel coronary disease who have either diabetes or the metabolic syndrome to either methotrexate or placebo. These two trials will primarily evaluate the role of anti-inflammatory treatments in risk of arterial events, but also expect to provide important information on the role of inflammation reduction in the occurrence of VTE.
